Skip to main content
LQDA
NASDAQ Life Sciences

Director Sells $12.8M in Liquidia Stock Amidst Recent Highs

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$64.69
Mkt Cap
$5.683B
52W Low
$11.85
52W High
$66.775
52W Position info
446% above low
Off High info
3.1% below high
Rel. Volume info
2.1× avg
Market data snapshot near publication time

LQDA has more than doubled off its 52-week low of $11.85 on elevated volume (2.1× avg).

Summary

Director Paul B. Manning sold $12.78 million of Liquidia Corp common stock on the open market, continuing a trend of insider selling while the stock trades near its 52-week high.


Key Events · Ownership and Investor Activity · LQDA

  • Director Sells Significant Stake

    Director Paul B. Manning disposed of 200,000 shares of common stock in open market sales, totaling $12,782,059.

  • Sales Near 52-Week Highs

    The transactions occurred on June 4, 2026, at prices ranging from $62.62 to $64.42, while the stock is trading near its 52-week high of $66.775.

  • Follows Insider Selling Trend

    This Form 4 filing follows a series of Form 144 filings by director-affiliated entities, indicating a broader pattern of insider selling activity in recent months.


Analysis · LQDA · Life Sciences

Director Paul B. Manning sold a substantial $12.78 million in company stock. This open market sale, occurring near the company's 52-week high, follows a trend of significant insider selling activity, including multiple Form 144 filings from director-affiliated entities in recent weeks. While the company recently announced its inclusion in the S&P SmallCap 600 Index, this large sale by a director could be interpreted as a move to lock in gains during a period of strength.

How filings like this one have moved

In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LQDA was trading at $64.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7B. The 52-week trading range was $11.85 to $66.78. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LQDA - Latest Insights

LQDA
Sep 30, 2026, 1:20 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $53.22
Real-time Price: $30.30 info
Change: -$22.92 (-43%) info
Market Cap: $6.327B info
LQDA
Sep 30, 2026, 11:42 AM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $53.22
Real-time Price: $30.30 info
Change: -$22.92 (-43%) info
Market Cap: $6.327B info
LQDA
Sep 03, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $70.20
Real-time Price: $30.30 info
Change: -$39.90 (-57%) info
Market Cap: $6.327B info
LQDA
Sep 03, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $72.17
Real-time Price: $30.30 info
Change: -$41.87 (-58%) info
Market Cap: $6.327B info
LQDA
Aug 12, 2026, 6:45 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $87.00
Real-time Price: $30.30 info
Change: -$56.70 (-65%) info
Market Cap: $6.327B info